Armata Pharmaceuticals Q1 EPS $(0.69) Misses $(0.31) Estimate, Sales $966.00K Miss $1.10M Estimate
Portfolio Pulse from Benzinga Newsdesk
Armata Pharmaceuticals (AMEX:ARMP) reported Q1 EPS of $(0.69), missing estimates by 122.58% and a 72.5% decrease from last year. Sales were $966K, missing estimates by 12.18% but a 21.36% increase from last year.
May 07, 2024 | 8:41 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Armata Pharmaceuticals reported a significant miss in Q1 EPS and sales, with a notable decrease in EPS from the previous year but an increase in sales.
The significant miss in both EPS and sales estimates, coupled with a substantial decrease in EPS from the previous year, is likely to negatively impact investor sentiment and stock price in the short term. However, the increase in sales year-over-year may provide some positive outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100